Protara Therapeutics, Inc. (NASDAQ:TARA) Insider Sells $96,144.72 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 21,224 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now directly owns 98,861 shares of the company’s stock, valued at $447,840.33. This trade represents a 17.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Protara Therapeutics Price Performance

Shares of TARA opened at $4.58 on Monday. The firm has a market capitalization of $168.39 million, a P/E ratio of -1.62 and a beta of 1.69. Protara Therapeutics, Inc. has a one year low of $1.60 and a one year high of $10.48. The business has a fifty day moving average of $4.27 and a 200 day moving average of $3.68.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. Analysts expect that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Institutional Trading of Protara Therapeutics

Several large investors have recently added to or reduced their stakes in the business. HBK Investments L P bought a new position in Protara Therapeutics in the fourth quarter worth approximately $106,000. Squarepoint Ops LLC bought a new stake in shares of Protara Therapeutics during the 4th quarter valued at $110,000. Dimensional Fund Advisors LP purchased a new stake in shares of Protara Therapeutics in the 4th quarter worth $111,000. Bailard Inc. bought a new position in Protara Therapeutics in the 4th quarter worth $157,000. Finally, XTX Topco Ltd purchased a new position in Protara Therapeutics during the third quarter valued at $60,000. 38.13% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on TARA. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Thursday, March 6th. Lifesci Capital assumed coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price objective for the company. Guggenheim restated a “buy” rating and set a $20.00 target price on shares of Protara Therapeutics in a research note on Friday, December 6th. Finally, Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a research note on Friday, March 14th. They issued an “overweight” rating for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, Protara Therapeutics has an average rating of “Buy” and an average target price of $22.50.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.